Responses
Cardiovascular Disease Clinical Research
Related Pharmaceutical Clinical Research
GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes
Compose a Response to This Article
Other responses
No responses have been published for this article.